TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21162508

Group type: EXPERIMENTAL
Intervention: Posterior soft tissue repair
Number of subjects: 276

Group type: COMPARATOR
Intervention: No posterior soft tissue repair
Number of subjects: 276
Study: 19123324

Group type: EXPERIMENTAL
Intervention: Hallux-trampling (HT) plus Yaotongling suppository (YS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hallux-trampling (HT) plus placebo suppository
Number of subjects: 108

Group type: COMPARATOR
Intervention: Yaotongling suppository (YS) plus mock HT
Number of subjects: 108
Study: 17704027

Group type: EXPERIMENTAL
Intervention: Purple sweet potato leaves (PSPLs) diet (daily consumption of 200 g PSPLs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet (low polyphenol, with carotenoids adjusted to PSPLs level)
Number of subjects: 15
Study: 12602532

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (477 mg twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (954 mg during short study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (in short study)
Number of subjects: 18
Study: 10827374

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 67000

Group type: EXPERIMENTAL
Intervention: Single-factor subgroup analyses
Number of subjects: 67000

Group type: EXPERIMENTAL
Intervention: Multifactorial prognostic subgroups
Number of subjects: 67000
Study: 9236628

Group type: EXPERIMENTAL
Intervention: Triple-dose Gd-DTPA (0.3 mmol/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single-dose Gd-DTPA with MT and short delay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple-dose Gd-DTPA with MT and short delay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MT imaging with long delay following triple-dose Gd-DTPA
Number of subjects: 50
Study: 8398056

Group type: EXPERIMENTAL
Intervention: Talcid suspension (hydrotalcit)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3096543

Group type: EXPERIMENTAL
Intervention: Humphrey A.D.E. system (Mapleson 'E' mode, lever down)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bain system (Mapleson D/E)
Number of subjects: 10
Study: 29874972

Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no laser therapy)
Number of subjects: 15
Study: 26757270

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg qd + promestriene vaginal capsules intravaginally (Group A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Solifenacin 5 mg qd (Group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 24962003

Group type: EXPERIMENTAL
Intervention: 120 mmol l(‐1) Na(+)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 180 mmol l(‐1) Na(+)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 60 mmol l(‐1) Na(+)
Number of subjects: 8
Study: 22966894

Group type: EXPERIMENTAL
Intervention: Shared decision making training for general practitioners
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (usual treatment)
Number of subjects: 1200
Study: 19679506

Group type: EXPERIMENTAL
Intervention: Prone Hip Extension with abdominal hollowing and active GM contraction for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prone Hip Extension only (control group)
Number of subjects: 20
Study: 18774563

Group type: EXPERIMENTAL
Intervention: Group 1: IUD guidance during hysteroscopic adhesiolysis with early intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Group 2: IUD guidance during hysteroscopic adhesiolysis without early intervention
Number of subjects: 71
Study: 16195478

Group type: EXPERIMENTAL
Intervention: LPLS447X carriers
Number of subjects: 10
Study: 12952998

Group type: EXPERIMENTAL
Intervention: Ethics consultation offered (n = 278)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Usual care (n = 273)
Number of subjects: 551
Study: 10801917

Group type: EXPERIMENTAL
Intervention: Minimally heated tomatoes (not homogenized)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mildly heated tomatoes (mildly homogenized)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Extensively heated tomatoes (severely homogenized)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Additional heating (compared to minimal heating)
Number of subjects: 33
Study: 8699333

Group type: EXPERIMENTAL
Intervention: Granulated tablet formulation of nadolol (80 mg) - single dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compressed tablet formulation of nadolol (80 mg) - single dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Granulated tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compressed tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Number of subjects: 20
Study: 1379056

Group type: EXPERIMENTAL
Intervention: Ephedrine 17.5 mg and 3% Dextran 70 7.5 ml kg‐1 before delivery (group A)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Volume loading with Dextran 15 ml kg‐1 without infusion of ephedrine (group B)
Number of subjects: 2
Study: 6384466

Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by flap procedures
Number of subjects: 17

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Scaling and root planing alone and scaling and root planing followed by flap procedures
Number of subjects: 17
Study: 30935296

Group type: EXPERIMENTAL
Intervention: Deload-tape
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sham-tape
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-tape
Number of subjects: 27
Study: 29938898

Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27054860

Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste and 0.075% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste and CPC mouthrinse
Number of subjects: 36
Study: 23810648

Group type: EXPERIMENTAL
Intervention: Kenneth Jones ACL reconstruction
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kenneth Jones ACL reconstruction + extra-articular ilio-tibial band tenodesis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Kenneth Jones ACL reconstruction alone
Number of subjects: 120
Study: 21910547

Group type: EXPERIMENTAL
Intervention: Morning administration of TOVA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Afternoon administration of TOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of inattention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of hyperactivity and impulsivity
Number of subjects: 0
Study: 20974316

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30, 60, and 90 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 or 60 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexlansoprazole 60 and 90 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18726104

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous gentamicin, administered 30 min before surgery.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics).
Number of subjects: 88
Study: 15652875

Group type: EXPERIMENTAL
Intervention: Repetitive TMS (rTMS) at 5 Hz, 20 sessions (5 sessions per week) of 120% of motor threshold and 1250 pulses per session, concomitantly taking amitriptyline (mean dose 110 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham repetitive TMS (sham)
Number of subjects: 46
Study: 11942669

Group type: EXPERIMENTAL
Intervention: PPE level A
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PPE level B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Workload task
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PPE levels A and B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heart rate during workload task
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sway measurements
Number of subjects: 16
Study: 9470324

Group type: COMPARATOR
Intervention: Phenytoin sodium (Dilantin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brand A
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brand C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Brand B
Number of subjects: 16
Study: 7637405

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 686

Group type: COMPARATOR
Intervention: Other providers (medical doctors)
Number of subjects: 686
Study: 2719366

Group type: EXPERIMENTAL
Intervention: Actidose‐Aqua 25 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Super Char 25 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no charcoal)
Number of subjects: 12
Study: 53428

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (H.B.I.G.)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Immune serum globulin (I.S.G.)
Number of subjects: 561
Study: 31565952

Group type: EXPERIMENTAL
Intervention: Topical silicone gel only
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Pressure garment therapy only
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combined topical silicone gel and pressure garment therapy
Number of subjects: 153
Study: 31021419

Group type: EXPERIMENTAL
Intervention: Maternal perception of excessive infant crying at 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vulnerable adult attachment style, previous maternal mental health difficulties, low paternal education, paternal involvement with the child, and not being married
Number of subjects: 0
Study: 24806033

Group type: EXPERIMENTAL
Intervention: TVR 2250 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: TVR 1500 mg
Number of subjects: 81
Study: 23257888

Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% levobupivacaine injected at T10, T11, and T12 paravertebral spaces
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 ml of 0.9% NaCl solution
Number of subjects: 60
Study: 21329495

Group type: EXPERIMENTAL
Intervention: Quarterly report card mailings
Number of subjects: 5457

Group type: EXPERIMENTAL
Intervention: Point-of-care distribution of report cards
Number of subjects: 5457

Group type: EXPERIMENTAL
Intervention: Patient-level provider performance feedback
Number of subjects: 5457

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 5457
Study: 19253124

Group type: EXPERIMENTAL
Intervention: LNIT with Der p-coated strips
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16572610

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg (oral preoperative dose)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ketoprofen 100 mg (2 IM doses before surgery and after 12 hours)
Number of subjects: 77
Study: 10394514

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 74
Study: 8742199

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study: 1679449

Group type: EXPERIMENTAL
Intervention: n-propanol (50% v/v) and isopropanol (30% v/v) with cosmetic additives
Number of subjects: 20

Group type: COMPARATOR
Intervention: isopropanol 60% v/v (standard control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: n-propanol (50% v/v) and isopropanol (30% v/v) without cosmetic additives
Number of subjects: 20
Study: 6310241

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (mean dose 0.5 micrograms daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: D3 (dose 100 micrograms daily)
Number of subjects: 17
Study: 31731109

Group type: EXPERIMENTAL
Intervention: Retigabine (300-1200 mg/day)
Number of subjects: 685
Study: 31399047

Group type: EXPERIMENTAL
Intervention: Individual face-to-face brief motivational interviewing (MI) with generic advice on selected health behaviour, plus brief MI messages via WhatsApp/WeChat for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with no MI and booster interventions
Number of subjects: 60
Study: 29893182

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) delivered in group sessions once a week for eight weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard treatment with citalopram (30-50 mg/day at therapeutic dosages)
Number of subjects: 48
Study: 26231684

Group type: EXPERIMENTAL
Intervention: CICADA method (CeasIng Cpap At standarD criteriA)
Number of subjects: 50
Study: 24939812

Group type: EXPERIMENTAL
Intervention: Functional assessment and immediate rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional assessment and rehabilitation as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment as usual and immediate rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment and rehabilitation as usual
Number of subjects: 0
Study: 22463125

Group type: EXPERIMENTAL
Intervention: 12-week intensive intervention of nutrition and exercise education, coping skills training and exercise (Phase I), followed by 9 months of continued monthly contact (Phase II) and then 6 months follow-up on their own.
Number of subjects: 358

Group type: COMPARATOR
Intervention: Experimental group (receiving the intervention)
Number of subjects: 358
Study: 20135645

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 140

Group type: COMPARATOR
Intervention: Other NSAIDs
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aspirin, Statins, Other NSAIDs
Number of subjects: 140
Study: 18084988

Group type: EXPERIMENTAL
Intervention: Modified fascia iliaca compartment block with 30 ml 0.5% bupivacaine with 1:200,000 adrenaline, 150 microg clonidine and 9 ml 0.9% saline
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group receiving 40 ml 0.9% saline
Number of subjects: 44
Study: 16046714

Group type: EXPERIMENTAL
Intervention: FOS/fiber formula (5.1 g/L FOS and 8.9 g/L fiber)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FOS/fiber formula
Number of subjects: 10
Study: 12404081

Group type: EXPERIMENTAL
Intervention: Caffeine (65 mg) consumed in de-caffeinated coffee at 1000, 1100, 1200, and 1300 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg) consumed at 1300 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (de-caffeinated coffee)
Number of subjects: 24
Study: 11783152

Group type: EXPERIMENTAL
Intervention: Puerarin with conventional treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 0
Study: 7848120

Group type: EXPERIMENTAL
Intervention: 6 mg of subcutaneous sumatriptan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable (control group during attack)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable (control group after treatment)
Number of subjects: 20
Study: 1983346

Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with ranitidine 300 mg q.d.s.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with ranitidine 1200 mg o.m.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: high-dose H2-blockade with sufotidine 600 mg b.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 30994312

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (Control)
Number of subjects: 64
Study: 30031272

Group type: EXPERIMENTAL
Intervention: Implicit training method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Explicit training method
Number of subjects: 20
Study: 26689707

Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (everolimus- or zotarolimus-eluting stent)
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Early-generation drug-eluting stents (paclitaxel- or sirolimus-eluting stent)
Number of subjects: 1257
Study: 25311699

Group type: EXPERIMENTAL
Intervention: Metofluthrin mosquito coils (spatial repellent)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo mosquito coils
Number of subjects: 180
Study: 23049928

Group type: EXPERIMENTAL
Intervention: Weekly text message support intervention
Number of subjects: 271
Study: 20948256

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with S‐1 (more than 50% of the total scheduled dose)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with S‐1 (less than 50% of the total scheduled dose)
Number of subjects: 47
Study: 17635756

Group type: EXPERIMENTAL
Intervention: Intensive multiple risk factor modification (targeting hypercholesterolaemia, hyperhomocysteinaemia, anaemia and disordered bone mineral metabolism)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 16139403

Group type: EXPERIMENTAL
Intervention: Intact limb (amputee)
Number of subjects: 9
Study: 12391370

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9973590

Group type: EXPERIMENTAL
Intervention: 12-week aerobic fitness program using bicycle ergometry
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 7547855

Group type: EXPERIMENTAL
Intervention: Liquid fibre (LF) 300 ml
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Liquid fibre (LF)
Number of subjects: 17
Study: 2127790

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐interferon (5 mega units thrice weekly for 2 months, then 1.5 mega units until the eighteenth month)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐interferon
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 30
Study: 369926

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 111
Study: 31715582

Group type: EXPERIMENTAL
Intervention: Individualized F‐V profile‐based training (2 sessions over 9 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standardized training regimen (control group, 10 participants)
Number of subjects: 46
Study: 31487208

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 498
Study: 28784841

Group type: EXPERIMENTAL
Intervention: ICU-specific written sign-out template
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual ICU sign-out
Number of subjects: 0
Study: 25852206

Group type: EXPERIMENTAL
Intervention: EPA+DHA (3.9 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23298459

Group type: EXPERIMENTAL
Intervention: Instructional sets emphasizing concussion history or gender (specifics on dosage and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral instructions (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender stereotype condition (specifics on dosage and duration not available)
Number of subjects: 0
Study: 21784390

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Driver bare-metal stent (BMS)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES) vs Driver bare-metal stent (BMS)
Number of subjects: 476
Study: 19270260

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 17383013

Group type: EXPERIMENTAL
Intervention: Higher levels of EPA and DHA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: DHA and EPA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: alpha‐LNA
Number of subjects: 105
Study: 15172862

Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine (3 mL of buffered 2% lidocaine solution)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 127
Study: 11510780

Group type: EXPERIMENTAL
Intervention: Pressurization rate at 5 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pressurization rate at 15 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lowest pressurization rate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Other pressurization rates (excluding lowest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gas exchange
Number of subjects: 10
Study: 9928572

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support
Number of subjects: 1

Group type: COMPARATOR
Intervention: Standard dose treatment
Number of subjects: 1
Study: 7830545

Group type: EXPERIMENTAL
Intervention: Degni‐Cordeiro's microsurgical indirect lymphatico‐venous shunt (L.V.S.) surgery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fasciotomies along the posterior aspect of the forearm
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple fasciotomies alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kondoleon's partial superficial lymphangectomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Servelle's total superficial lymphangectomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 36
Study: 3061400

Group type: EXPERIMENTAL
Intervention: More frequent clinical follow-ups without changing dietary intake of protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (implied control)
Number of subjects: 0
Study: 29709643

Group type: EXPERIMENTAL
Intervention: Peanut oral food challenge (OFC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CD63 ratio
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: History of exercise-induced asthma
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FEV1/FVC ratio
Number of subjects: 120